Protein kinases CK1 and CK2 as new targets for neurodegenerative diseases
暂无分享,去创建一个
[1] N. Gray,et al. Targeting cancer with small molecule kinase inhibitors , 2009, Nature Reviews Cancer.
[2] Specificity and Regulation of Casein Kinase-Mediated Phosphorylation of &agr;-Synuclein , 2008 .
[3] G. Forloni,et al. JNK signalling: a possible target to prevent neurodegeneration. , 2007, Current pharmaceutical design.
[4] L Meijer,et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. , 1997, European journal of biochemistry.
[5] E. de Moliner,et al. Structural features underlying selective inhibition of protein kinase CK2 by ATP site‐directed tetrabromo‐2‐benzotriazole , 2001, Protein science : a publication of the Protein Society.
[6] Barbara Guerra,et al. Protein kinase CK2 in human diseases. , 2008, Current medicinal chemistry.
[7] L. Johnson. Protein kinase inhibitors: contributions from structure to clinical compounds , 2009, Quarterly Reviews of Biophysics.
[8] I. Ferrer,et al. Combined kinase inhibition modulates parkin inactivation , 2008, Human molecular genetics.
[9] L. Pinna,et al. Rat liver Golgi apparatus contains a protein kinase similar to the casein kinase of lactating mammary gland. , 1997, European journal of biochemistry.
[10] James S. Duncan,et al. Tetrabromobenzotriazole (TBBt) and tetrabromobenzimidazole (TBBz) as selective inhibitors of protein kinase CK2: evaluation of their effects on cells and different molecular forms of human CK2. , 2005, Biochimica et biophysica acta.
[11] A. Zambon,et al. Development and exploitation of CK2 inhibitors , 2005, Molecular and Cellular Biochemistry.
[12] S. Moro,et al. Inhibition of protein kinase CK2 by condensed polyphenolic derivatives. An in vitro and in vivo study. , 2004, Biochemistry.
[13] O. Issinger,et al. Crystal structure of human protein kinase CK2: insights into basic properties of the CK2 holoenzyme , 2001, The EMBO journal.
[14] D. Litchfield. Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. , 2003, The Biochemical journal.
[15] James S. Duncan,et al. Too much of a good thing: the role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2. , 2008, Biochimica et biophysica acta.
[16] Margaret A. Pericak-Vance,et al. Hypothesis: Microtubule Instability and Paired Helical Filament Formation in the Alzheimer Disease Brain Are Related to Apolipoprotein E Genotype , 1994, Experimental Neurology.
[17] G. Unger,et al. Protein Kinase CK2 in Health and Disease , 2009, Cellular and Molecular Life Sciences.
[18] D. Shugar,et al. Selectivity of 4,5,6,7-tetrabromobenzimidazole as an ATP-competitive potent inhibitor of protein kinase CK2 from various sources. , 2003, Biochemical and biophysical research communications.
[19] H. Akiyama,et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. , 2006, Biochemical and biophysical research communications.
[20] C. Allende,et al. Protein kinase CK2: an enzyme with multiple substrates and a puzzling regulation , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[21] L. Pinna,et al. 2-Dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole: a novel powerful and selective inhibitor of protein kinase CK2. , 2004, Biochemical and biophysical research communications.
[22] L. J. Eldik,et al. Targeting protein kinases in central nervous system disorders , 2009, Nature Reviews Drug Discovery.
[23] Andreas Gocht,et al. The casein kinase 1 family: participation in multiple cellular processes in eukaryotes. , 2005, Cellular signalling.
[24] G. Halliday,et al. Phosphorylation of apolipoprotein-E at an atypical protein kinase CK2 PSD/E site in vitro. , 2005, Biochemistry.
[25] P. Bryant,et al. Casein Kinase I epsilon positively regulates the Akt pathway in breast cancer cell lines. , 2008, Biochemical and biophysical research communications.
[26] H. M. Farrell,et al. Casein kinase from the Golgi apparatus of lactating mammary gland. , 1974, The Journal of biological chemistry.
[27] D. Gomez,et al. Systemic administration of a peptide that impairs the protein kinase (CK2) phosphorylation reduces solid tumor growth in mice , 2008, International journal of cancer.
[28] O. Issinger,et al. Protein kinase CK2: from structures to insights , 2009, Cellular and Molecular Life Sciences.
[29] U. Knippschild,et al. Anti-apoptotic and growth-stimulatory functions of CK1 delta and epsilon in ductal adenocarcinoma of the pancreas are inhibited by IC261 in vitro and in vivo , 2008, Gut.
[30] Sang-Hyeon Lee,et al. Casein Kinase II-mediated Phosphorylation Regulates α-Synuclein/Synphilin-1 Interaction and Inclusion Body Formation* , 2004, Journal of Biological Chemistry.
[31] S. Harper,et al. MAPKs: new targets for neurodegeneration , 2003, Expert opinion on therapeutic targets.
[32] P. Cohen,et al. D4476, a cell‐permeant inhibitor of CK1, suppresses the site‐specific phosphorylation and nuclear exclusion of FOXO1a , 2004, EMBO reports.
[33] Laurie A. Smith,et al. Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine , 2006, Nature.
[34] P. Lockhart,et al. RING finger 1 mutations in Parkin produce altered localization of the protein. , 2003, Human molecular genetics.
[35] I. Churcher. Tau therapeutic strategies for the treatment of Alzheimer's disease. , 2006, Current topics in medicinal chemistry.
[36] Y. Wong,et al. Identification of chemical inhibitors of protein-kinase CK2 subunit interaction , 2008, Molecular and Cellular Biochemistry.
[37] M. Pericak-Vance,et al. Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[38] O. Issinger,et al. Inclining the purine base binding plane in protein kinase CK2 by exchanging the flanking side-chains generates a preference for ATP as a cosubstrate. , 2005, Journal of molecular biology.
[39] H. Akiyama,et al. Identification of casein kinase-1 phosphorylation sites on TDP-43. , 2009, Biochemical and biophysical research communications.
[40] U. Knippschild,et al. p53 is phosphorylated in vitro and in vivo by the delta and epsilon isoforms of casein kinase 1 and enhances the level of casein kinase 1 delta in response to topoisomerase-directed drugs , 1997, Oncogene.
[41] D. Fabbro,et al. Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA). , 2003, The Biochemical journal.
[42] R. Weinmann,et al. Casein kinase type II is involved in the inhibition by 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole of specific RNA polymerase II transcription. , 1986, The Journal of biological chemistry.
[43] J. Kuret,et al. Casein kinase 1 delta is associated with pathological accumulation of tau in several neurodegenerative diseases , 2000, Neurobiology of Aging.
[44] L. Pinna,et al. Features and potentials of ATP-site directed CK2 inhibitors. , 2005, Biochimica et biophysica acta.
[45] Mohammed M. Abadleh,et al. 3,4-Diaryl-isoxazoles and -imidazoles as potent dual inhibitors of p38alpha mitogen activated protein kinase and casein kinase 1delta. , 2009, Journal of medicinal chemistry.
[46] E. de Moliner,et al. The Replacement of ATP by the Competitive Inhibitor Emodin Induces Conformational Modifications in the Catalytic Site of Protein Kinase CK2* , 2000, The Journal of Biological Chemistry.
[47] P. Blanquet. Casein kinase 2 as a potentially important enzyme in the nervous system , 2000, Progress in Neurobiology.
[48] F. Chaverneff,et al. Casein kinase II contributes to the synergistic effects of BMP7 and BDNF on Smad 1/5/8 phosphorylation in septal neurons under hypoglycemic stress , 2009, Journal of neurochemistry.
[49] T. Hunter,et al. The Protein Kinase Complement of the Human Genome , 2002, Science.
[50] Ana Martínez,et al. GSK-3 inhibitors: a ray of hope for the treatment of Alzheimer's disease? , 2008, Journal of Alzheimer's disease : JAD.
[51] H. Wiśniewski,et al. Amyloid β-protein stimulates casein kinase I and casein kinase II activities , 1993, Brain Research.
[52] E. Eide,et al. CASEIN KINASE I: ANOTHER COG IN THE CIRCADIAN CLOCKWORKS , 2001, Chronobiology international.
[53] J. Ávila,et al. Glycogen synthase kinase 3 phosphorylation of different residues in the presence of different factors: Analysis on tau protein , 1996, Molecular and Cellular Biochemistry.
[54] J. Busciglio,et al. Disruption of fast axonal transport is a pathogenic mechanism for intraneuronal amyloid beta , 2009, Proceedings of the National Academy of Sciences.
[55] P. Graves,et al. Role of COOH-terminal Phosphorylation in the Regulation of Casein Kinase Iδ (*) , 1995, The Journal of Biological Chemistry.
[56] Christopher R. Jones,et al. Modeling of a Human Circadian Mutation Yields Insights into Clock Regulation by PER2 , 2007, Cell.
[57] M. Price,et al. CKI, there's more than one: casein kinase I family members in Wnt and Hedgehog signaling. , 2006, Genes & development.
[58] V. Pillay,et al. Trends in the Molecular Pathogenesis and Clinical Therapeutics of Common Neurodegenerative Disorders , 2009, International journal of molecular sciences.
[59] D. Selkoe,et al. Dopamine covalently modifies and functionally inactivates parkin , 2005, Nature Medicine.
[60] M. Cosentino,et al. Anti-AIDS agents. 46. Anti-HIV activity of harman, an anti-HIV principle from Symplocos setchuensis, and its derivatives. , 2001, Journal of natural products.
[61] P. Cohen. Protein kinases — the major drug targets of the twenty-first century? , 2002, Nature reviews. Drug discovery.
[62] K. Jellinger,et al. Neuropathology of Alzheimer's disease: a critical update. , 1998, Journal of neural transmission. Supplementum.
[63] Dong Wan Kim,et al. Localization of CKII β subunits in Lewy bodies of Parkinson's disease , 2008, Journal of the Neurological Sciences.
[64] J. Kuret,et al. Casein Kinase 1 Delta Phosphorylates Tau and Disrupts Its Binding to Microtubules* , 2004, Journal of Biological Chemistry.
[65] P. Colas,et al. p53-dependent inhibition of mammalian cell survival by a genetically selected peptide aptamer that targets the regulatory subunit of protein kinase CK2 , 2006, Oncogene.
[66] J. Kuret,et al. A new molecular link between the fibrillar and granulovacuolar lesions of Alzheimer's disease. , 1999, The American journal of pathology.
[67] J. Bain,et al. The selectivity of inhibitors of protein kinase CK2: an update. , 2008, The Biochemical journal.
[68] Laurent Meijer,et al. Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials. , 2003, Accounts of chemical research.
[69] J. Kuret,et al. Casein kinase-1 isoforms differentially associate with neurofibrillary and granulovacuolar degeneration lesions , 2006, Acta Neuropathologica.
[70] L. C. Robinson,et al. Casein kinase I-like protein kinases encoded by YCK1 and YCK2 are required for yeast morphogenesis , 1993, Molecular and cellular biology.
[71] R. Llinás,et al. Synaptic transmission block by presynaptic injection of oligomeric amyloid beta , 2009, Proceedings of the National Academy of Sciences.
[72] J. Kuret,et al. Casein kinase 1 delta mRNA is upregulated in Alzheimer disease brain , 2000, Brain Research.
[73] Dong Wan Kim,et al. Localization of CKII beta subunits in Lewy bodies of Parkinson's disease. , 2008, Journal of the neurological sciences.
[74] P. Blanquet,et al. Neurotrophin-induced activation of casein kinase 2 in rat hippocampal slices , 1998, Neuroscience.
[75] L. Cesaro,et al. Protein kinase CK2: a newcomer in the 'druggable kinome'. , 2006, Biochemical Society transactions.
[76] V. Moucadel,et al. Identification of polyoxometalates as nanomolar noncompetitive inhibitors of protein kinase CK2. , 2008, Chemistry & biology.
[77] J. Graff,et al. Casein kinase I transduces Wnt signals , 1999, Nature.
[78] H. Yost,et al. Disease‐associated casein kinase I δ mutation may promote adenomatous polyps formation via a Wnt/β‐catenin independent mechanism , 2006 .
[79] S. Funayama,et al. Characterization of (-)-matairesinol as a potent inhibitor of casein kinase I in vitro. , 2003, Biological & pharmaceutical bulletin.
[80] G M Hathaway,et al. Cyclic nucleotide-independent protein kinases from rabbit reticulocytes. Purification of casein kinases. , 1979, The Journal of biological chemistry.
[81] S. Moro,et al. How Druggable Is Protein Kinase CK2 , 2010 .
[82] D. Alonso,et al. CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo , 2008, Molecular and Cellular Biochemistry.
[83] S. Nakajo,et al. Purification and characterization of two cyclic AMP-independent protein kinases from AH-66 hepatoma ascites cells. , 1984, Journal of Biochemistry (Tokyo).
[84] D. Alonso,et al. Antitumor Effect of a Novel Proapoptotic Peptide that Impairs the Phosphorylation by the Protein Kinase 2 (Casein Kinase 2) , 2004, Cancer Research.
[85] G. Dobrowolska,et al. Benzimidazole nucleoside analogues as inhibitors of plant (maize seedling) casein kinases. , 1991, Biochimica et biophysica acta.
[86] R. Prudent,et al. New protein kinase CK2 inhibitors: jumping out of the catalytic box. , 2009, Chemistry & biology.
[87] L Meijer,et al. Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent. , 2000, Chemistry & biology.
[88] R. Webster,et al. CK2beta gene silencing increases cell susceptibility to influenza A virus infection resulting in accelerated virus entry and higher viral protein content , 2008, Journal of molecular signaling.
[89] J. Bain,et al. Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. , 2004, Journal of medicinal chemistry.
[90] L. Meijer,et al. Synthesis and kinase inhibitory activity of novel substituted indigoids. , 2009, Bioorganic & medicinal chemistry.
[91] T. Dawson,et al. Response to Comment on "S-Nitrosylation of Parkin Regulates Ubiquitination and Compromises Parkin's Protective Function" , 2005, Science.
[92] Brent R Stockwell,et al. Inhibition of casein kinase 1-epsilon induces cancer-cell-selective, PERIOD2-dependent growth arrest , 2008, Genome Biology.
[93] L. Meijer,et al. Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein. , 2000, The Journal of biological chemistry.
[94] Bourguet-Kondracki Ml,et al. Marine pharmacology: potentialities in the treatment of infectious diseases, osteoporosis and Alzheimer's disease. , 2005, Advances in biochemical engineering/biotechnology.
[95] Kit-Yi Leung,et al. Novel Phosphorylation Sites in Tau from Alzheimer Brain Support a Role for Casein Kinase 1 in Disease Pathogenesis* , 2007, Journal of Biological Chemistry.
[96] E. Waxman,et al. Specificity and Regulation of Casein Kinase-Mediated Phosphorylation of &agr;-Synuclein , 2008, Journal of neuropathology and experimental neurology.
[97] Georgios Giamas,et al. The Role of the Casein Kinase 1 (CK1) Family in Different Signaling Pathways Linked to Cancer Development , 2005, Oncology Research and Treatment.
[98] E. Pérez-Payá,et al. ATP‐Noncompetitive Inhibitors of CDK–Cyclin Complexes , 2009, ChemMedChem.
[99] D. Shugar,et al. Halogenated benzimidazoles and benzotriazoles as selective inhibitors of protein kinases CK I and CK II from Saccharomyces cerevisiae and other sources. , 1995, Biochemical and biophysical research communications.
[100] Helmut Mack,et al. Rho kinase, a promising drug target for neurological disorders , 2005, Nature Reviews Drug Discovery.
[101] N. Matsuki,et al. Protein kinase CK2 modulates synaptic plasticity by modification of synaptic NMDA receptors in the hippocampus , 2008, The Journal of physiology.
[102] M. Budini,et al. Autophosphorylation of carboxy‐terminal residues inhibits the activity of protein kinase CK1α , 2009, Journal of cellular biochemistry.
[103] Takashi Uehara,et al. Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[104] D. Fabbro,et al. Discovery of a potent and selective protein kinase CK2 inhibitor by high-throughput docking. , 2003, Journal of medicinal chemistry.
[105] S. Moro,et al. Quinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2. , 2009, The Biochemical journal.
[106] L. Meijer,et al. Constitutive Phosphorylation of the Parkinson's Disease Associated α-Synuclein* , 2000, The Journal of Biological Chemistry.
[107] Houeto Jean-Luc. [Parkinson's disease]. , 2022, La Revue du praticien.
[108] Alessandra Gianoncelli,et al. Identification of novel protein kinase CK1 delta (CK1delta) inhibitors through structure-based virtual screening. , 2008, Bioorganic & medicinal chemistry letters.
[109] D. Flaherty,et al. Phosphorylation of human tau protein by microtubule‐associated kinases: GSK3β and cdk5 are key participants , 2000, Journal of neuroscience research.
[110] M. Engwall,et al. Inhibition of casein kinase I ε/δ produces phase shifts in the circadian rhythms of Cynomolgus monkeys , 2009, Psychopharmacology.
[111] E. P. Kennedy,et al. The enzymatic phosphorylation of proteins. , 1954, The Journal of biological chemistry.
[112] S. Moro,et al. Inhibition of Protein Kinase CK2 by Anthraquinone-related Compounds , 2003, The Journal of Biological Chemistry.
[113] Christopher Haslett,et al. Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis , 2006, Nature Medicine.
[114] D. Litchfield,et al. The Regulatory β Subunit of Protein Kinase CK2 Mediates Formation of Tetrameric CK2 Complexes* , 2000, Journal of Biological Chemistry.
[115] J. Staropoli,et al. Tumorigenesis and neurodegeneration: two sides of the same coin? , 2008, BioEssays : news and reviews in molecular, cellular and developmental biology.
[116] M. Hagiwara,et al. A newly synthesized selective casein kinase I inhibitor, N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide, and affinity purification of casein kinase I from bovine testis. , 1989, The Journal of biological chemistry.
[117] Aj Lees,et al. Parkinson's disease (vol 373, pg 2055, 2009) , 2009 .
[118] L. Mouawad,et al. Expanding the chemical diversity of CK2 inhibitors , 2008, Molecular and Cellular Biochemistry.
[119] P. Greengard,et al. Regulation of Alzheimer's disease amyloid-beta formation by casein kinase I. , 2007, Proceedings of the National Academy of Sciences of the United States of America.
[120] A. Brunati,et al. Polyhalogenobenzimidazoles: synthesis and their inhibitory activity against casein kinases. , 2003, Bioorganic & medicinal chemistry.
[121] Margaret G. Distler,et al. A role for casein kinase 1 epsilon in the locomotor stimulant response to methamphetamine , 2009, Psychopharmacology.
[122] P. Steinacker,et al. Neurochemical Approaches in the Laboratory Diagnosis of Parkinson and Parkinson Dementia Syndromes: A Review , 2009, CNS neuroscience & therapeutics.
[123] O. Issinger,et al. The CK2 alpha/CK2 beta interface of human protein kinase CK2 harbors a binding pocket for small molecules. , 2008, Chemistry & biology.
[124] E. Masliah,et al. Aberrant casein kinase II in Alzheimer's disease , 1990, Brain Research.
[125] Caroline Barette,et al. Structure-based design of small peptide inhibitors of protein kinase CK2 subunit interaction. , 2007, The Biochemical journal.
[126] L. Pinna,et al. Ribofuranosyl-benzimidazole derivatives as inhibitors of casein kinase-2 and casein kinase-1. , 1990, European journal of biochemistry.
[127] L. Pinna,et al. One‐thousand‐and‐one substrates of protein kinase CK2? , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[128] Eric Schaeffer,et al. An inhibitor of casein kinase I epsilon induces phase delays in circadian rhythms under free-running and entrained conditions. , 2007, The Journal of pharmacology and experimental therapeutics.
[129] D. Virshup,et al. Identification of Inhibitory Autophosphorylation Sites in Casein Kinase I ε* , 1999, The Journal of Biological Chemistry.
[130] R. Regan,et al. Hemoglobin neurotoxicity is attenuated by inhibitors of the protein kinase CK2 independent of heme oxygenase activity. , 2008, Current neurovascular research.
[131] T. Ebisawa,et al. Circadian rhythms in the CNS and peripheral clock disorders: human sleep disorders and clock genes. , 2007, Journal of pharmacological sciences.
[132] P. Graves,et al. Phosphate groups as substrate determinants for casein kinase I action. , 1990, The Journal of biological chemistry.
[133] L. Cesaro,et al. Mass spectrometry analysis of a protein kinase CK2beta subunit interactome isolated from mouse brain by affinity chromatography. , 2008, Journal of proteome research.
[134] Juan Fernandez-Recio,et al. Identifying interaction motifs in CK2beta--a ubiquitous kinase regulatory subunit. , 2006, Trends in biochemical sciences.
[135] Paul Greengard,et al. Physiological Role for Casein Kinase 1 in Glutamatergic Synaptic Transmission , 2005, The Journal of Neuroscience.
[136] Eric Schaeffer,et al. An Inhibitor of Casein Kinase Iϵ Induces Phase Delays in Circadian Rhythms under Free-Running and Entrained Conditions , 2007, Journal of Pharmacology and Experimental Therapeutics.
[137] Bourguet-Kondracki Ml,et al. Marine pharmacology: potentialities in the treatment of infectious diseases, osteoporosis and Alzheimer's disease. , 2005 .
[138] A. Mackinlay,et al. Protein kinase activity from lactating bovine mammary gland. , 1971, Biochimica et biophysica acta.
[139] Poonsakdi Ploypradith,et al. Anticancer Alkaloid Lamellarins Inhibit Protein Kinases , 2008, Marine drugs.
[140] C. Peschel,et al. Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells , 2004, Leukemia.
[141] P. Greengard,et al. Regulation of Alzheimer's disease amyloid-β formation by casein kinase I , 2007, Proceedings of the National Academy of Sciences.
[142] E. Masliah,et al. Casein kinase II is associated with neurofibrillary tangles but is not an intrinsic component of paired helical filaments , 1992, Brain Research.
[143] L. Pinna,et al. A structural insight into CK2 inhibition , 2008, Molecular and Cellular Biochemistry.
[144] S. K. Lee,et al. Emodin, an anthraquinone derivative isolated from the rhizomes of Rheum palmatum, selectively inhibits the activity of casein kinase II as a competitive inhibitor. , 1999, Planta medica.
[145] Olga Pletnikova,et al. Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin's protective function. , 2005, Human molecular genetics.
[146] S. Davies,et al. Selectivity of 4,5,6,7‐tetrabromobenzotriazole, an ATP site‐directed inhibitor of protein kinase CK2 (‘casein kinase‐2’) , 2001, FEBS letters.
[147] T. Saitoh,et al. Changes in Protein Kinases in Brain Aging and Alzheimer’s Disease , 1995, Drugs & Aging.
[148] P. Lampe,et al. The effects of connexin phosphorylation on gap junctional communication. , 2004, The international journal of biochemistry & cell biology.
[149] Laurent Meijer,et al. Meridianins, a new family of protein kinase inhibitors isolated from the ascidian Aplidium meridianum. , 2004, Bioorganic & medicinal chemistry letters.
[150] P. Cohen,et al. The selectivity of protein kinase inhibitors: a further update. , 2007, The Biochemical journal.
[151] B. Shan,et al. Different expression patterns of CK2 subunits in the brains of experimental animals and patients with transmissible spongiform encephalopathies , 2008, Archives of Virology.
[152] S. D. Gross,et al. Casein kinase I: spatial organization and positioning of a multifunctional protein kinase family. , 1998, Cellular signalling.
[153] S. Moro,et al. Toward the rational design of protein kinase casein kinase-2 inhibitors. , 2002, Pharmacology & therapeutics.
[154] Ruth Lehr,et al. Identification of novel inhibitors of the transforming growth factor beta1 (TGF-beta1) type 1 receptor (ALK5). , 2002, Journal of medicinal chemistry.
[155] Ji Luo,et al. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism , 2006, Nature Reviews Genetics.
[156] P. Greengard,et al. Roscovitine-derived, dual-specificity inhibitors of cyclin-dependent kinases and casein kinases 1. , 2008, Journal of medicinal chemistry.
[157] C. Slaughter,et al. Purification of casein kinase I and isolation of cDNAs encoding multiple casein kinase I-like enzymes. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[158] Martin Egli,et al. Crystal Structure of a Conformation-selective Casein Kinase-1 Inhibitor* , 2000, The Journal of Biological Chemistry.
[159] E. Masliah,et al. Casein kinase II alteration precedes tau accumulation in tangle formation. , 1992, The American journal of pathology.
[160] W. Pardridge. The blood-brain barrier: Bottleneck in brain drug development , 2005, NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics.
[161] H. Yost,et al. Disease-associated casein kinase I delta mutation may promote adenomatous polyps formation via a Wnt/beta-catenin independent mechanism. , 2007, International journal of cancer.
[162] D. Bechtold,et al. Setting Clock Speed in Mammals: The CK1ɛ tau Mutation in Mice Accelerates Circadian Pacemakers by Selectively Destabilizing PERIOD Proteins , 2008, Neuron.
[163] L. Pinna,et al. Tetraiodobenzimidazoles are potent inhibitors of protein kinase CK2. , 2009, Bioorganic & medicinal chemistry.
[164] O. Issinger,et al. Protein Kinase CK2 in Health and Disease , 2009, Cellular and Molecular Life Sciences.
[165] A. Loudon,et al. Selective Inhibition of Casein Kinase 1ϵ Minimally Alters Circadian Clock Period , 2009, Journal of Pharmacology and Experimental Therapeutics.